MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-16-2023
Athersys Total Non Current Liabilities 2011-2026 | ATHX
Annual Total Non Current Liabilities Athersys
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 5.4 M | 5.56 M | 3.14 M | 134 K | 1 M | 649 K | 3.13 M | 10 M | 2.88 M | 983 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10 M | 134 K | 3.29 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
383 M | $ 0.8 | -3.59 % | $ 36.6 M |  Israel |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
Exelixis
EXEL
|
63.6 M | $ 46.21 | -5.11 % | $ 12.5 B | USA |
 |
Fortress Biotech
FBIO
|
83.9 M | $ 2.4 | -5.88 % | $ 67 M | USA |
|
Forte Biosciences
FBRX
|
10.5 M | $ 26.17 | -1.32 % | $ 339 M | USA |
 |
Heron Therapeutics
HRTX
|
14.6 M | $ 1.24 | -5.34 % | $ 207 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
1.28 B | $ 76.02 | -1.08 % | $ 12.2 B | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 93.02 | -2.35 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
711 M | $ 210.33 | -9.55 % | $ 3.85 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 22.57 | 5.05 % | $ 3.74 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
50.3 M | $ 102.93 | -6.5 % | $ 5.17 B | USA |
 |
MannKind Corporation
MNKD
|
219 M | $ 3.55 | -0.28 % | $ 1.09 B | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 3.14 | -0.32 % | $ 653 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.54 | 5.67 % | $ 5.83 M | Israel |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Matinas BioPharma Holdings
MTNB
|
915 K | $ 0.65 | -5.15 % | $ 3.56 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 20.66 | -14.52 % | $ 2.63 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Genmab A/S
GMAB
|
769 M | $ 27.06 | -2.98 % | $ 16.7 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
854 K | - | 17.91 % | $ 11.1 M | USA |